Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Cited by 88 Publications

Cancer Cell, 2013, 23(6):839-52

PubMed: 23684459 ( click the link to review the publication )

Cell, 2012, 149(3):656-70

PubMed: 22920938 ( click the link to review the publication )

Dev Cell, 2019, 50(2):229-246

PubMed: 31204173 ( click the link to review the publication )

Cancer Lett, 2019, 447:93-104

PubMed: 30660646 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5334

PubMed: 31397884 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):356-363

PubMed: 30446585 ( click the link to review the publication )

Front Oncol, 2019, 9:422

PubMed: 31192127 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):739

PubMed: 29970892 ( click the link to review the publication )

Front Aging Neurosci, 2018, 10:378

PubMed: 30515090 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(11):1219-1229

PubMed: 30265530 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(8):748-756

PubMed: 29961813 ( click the link to review the publication )

BMC Neurosci, 2018, 19(1):52

PubMed: 30189852 ( click the link to review the publication )

Transl Cancer Res, 2018, 7(6):1548-1560

PubMed: 30761266 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169585

PubMed: 28081222 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173473

PubMed: 28291820 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(9):1343-1349

PubMed: 28597147 ( click the link to review the publication )

Sci Rep, 2017, 7:42062

PubMed: 28165023 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(6):3130-3145

PubMed: 27980063 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:305-313

PubMed: 27665476 ( click the link to review the publication )
Exp Cell Res, 2016, 340(1):81-90

PubMed: 26712518 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(1):54-60

PubMed: 27614310 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(4):1170-6

PubMed: 27073162 ( click the link to review the publication )

J Mol Neurosci, 2016, 59(4):567-78

PubMed: 27412469 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):1025-33

PubMed: 26269112 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.04.015

PubMed: 25934232 ( click the link to review the publication )

Mol Cell Biochem, 2015, 398(1-2):105-13

PubMed: 25223639 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3244-2

PubMed: 25697899 ( click the link to review the publication )

Oncoscience, 2015,

PubMed: ( click the link to review the publication )

Oncoscience, 2015, 10.1155/2015/8332

PubMed: ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.184.

PubMed: 24998847 ( click the link to review the publication )

FASEB J, 2014, 27(7):2584-99

PubMed: 23507869 ( click the link to review the publication )

Cardiovasc Diabetol, 2014, 35(7):450-4

PubMed: 24836459 ( click the link to review the publication )

Carcinogenesis, 2014, 35(10):2232-43

PubMed: 24942865 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(9):1851-64

PubMed: 24769208 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 450(1):646-51

PubMed: 24946212 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):362-7

PubMed: 25264192 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(1):72-8

PubMed: 25152399 ( click the link to review the publication )

Vet J, 2014, 201(1):83-90

PubMed: 24881508 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Lett, 2013, 336(2):319-24

PubMed: 23528835 ( click the link to review the publication )

Gynecol Oncol, 2013, 131(1):207-12

PubMed: 23877012 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1831(8):1322-34

PubMed: 23707264 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1828(5):1384-9

PubMed: 23376656 ( click the link to review the publication )

J Biol Chem, 2013, 288(31):22836-48

PubMed: 23788636 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Biochimie, 2013, 101:50-9

PubMed: 24394624 ( click the link to review the publication )

Oncol Rep, 2013, 29(6):2422-30

PubMed: 23588929 ( click the link to review the publication )

Biochemistry, 2013, 53(3):462-72

PubMed: 24383815 ( click the link to review the publication )

Dig Dis Sci, 2013, 58(10):2873-80

PubMed: 23912246 ( click the link to review the publication )

PLoS One, 2013, 8(5):e61896

PubMed: 23658701 ( click the link to review the publication )

PLoS One, 2013, 8(8): e74420

PubMed: 24009772 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 443(2):447-52

PubMed: 24316214 ( click the link to review the publication )

Mol Biol Rep, 2013, 40(10):5645-55

PubMed: 24065522 ( click the link to review the publication )

Mol Med Rep, 2013, 7(2):642-8

PubMed: 23175237 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 65(2):217-27

PubMed: 23015227 ( click the link to review the publication )
Cell Biochem Biophys, 2013, 66(3):737-46

PubMed: 23397419 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2012, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(12):1898-912

PubMed: 23001822 ( click the link to review the publication )

J Biol Chem, 2012, 286(43):37389-98

PubMed: 21908616 ( click the link to review the publication )

Expert Opin Inv Drugs, 2012, 21(11):1597-606

PubMed: ( click the link to review the publication )

Mol Carcinog, 2012, 52(9):667-75

PubMed: 22488590 ( click the link to review the publication )

Surgery, 2012, 152(6):1218-24

PubMed: 23158188 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(11):1009-17

PubMed: 22825337 ( click the link to review the publication )

PLoS Biol, 2011, 9(9):e1001148

PubMed: 21931533 ( click the link to review the publication )

Cancer Lett, 2011, 310(1):118-28

PubMed: 21775054 ( click the link to review the publication )

J Pharmacol Exp Ther, 2011, 336(3):866-73

PubMed: 21148684 ( click the link to review the publication )

Radiat Oncol, 2011, 6:39

PubMed: 21496273 ( click the link to review the publication )

Cancer Res, 2010, 70(22):9106-17

PubMed: 21062988 ( click the link to review the publication )

Brit J Pharmacol, 2010, 160(2):355-66

PubMed: 20423345 ( click the link to review the publication )

Cytotechnology, 2010, 62(5):449-60

PubMed: 20842425 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
T24 BC	NWDFbo1TTnWwY4Tpc44hSXO\|YYm=	Mn30NE42NzFxMj61JO69VQ>?	M2rubFMhcA>?	MVPy[YR2[2W\|IITo[UBj[XOjbDDDRkB1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36gcIV3\Wy\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NX:xXFNDOjZyOUe4O\|M>
T24 BC	MnjER4VtdCCYaXHibYxqfHliQYPzZZk>	NGrhRnAxNjVxMT:yMlUh\|ryP	NH7Te3AzPCCq	MmrW[Y5p[W6lZYOgd49z[W[nbnniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliZHXjdoVie2V?	M3;H[VI3ODl5OEez
T24 BC	NEHRdGdCeG:ydH;zbZMhSXO\|c3H5	Mnm0Nk42KM7:TR?=	M1jUR\|I1KGh?	NFrKS2R{\W6\|aYTpfoV{KEKFIHPlcIx{KHSxIIPvdoFn\W6rYj3pcoR2[2WmIHHwc5B1d3SrY9Mg	Mm\2NlYxQTd6N{O=
HepG2	NF7YTo9HfW6ldHnvckBCe3OjeR?=	NICyZoozOMLizszN	Mn7VNlTDqGh?	NIr4WXlxem:mdXPld{BidiCrboTlcpNmKGO7dH;wcIF{dWmlII\hZ5VwdGm8YYTpc44h[2:{cnXzdI9v\GmwZzD0c{BiKG6xdHHicIUh\GmuYYTheIlwdiCxZjD0bIUhTVJiY3nzeIVzdnN?	NELRRmgzPTl\|NEKzNi=>
U-87 MG	MVfGeY5kfGmxbjDBd5NigQ>?	M3T4O\|IxyqEQvF2=	NIXIcVAzPMLiaB?=	MWTpcoNz\WG\|ZYOg[I92[mynLX3lcYJz[W6nIHLveY5lKHO2coXjeJVz\XN?	MXSyOVk{PDJ\|Mh?=
HepG2	M1LqdmZ2dmO2aX;uJGF{e2G7	M37hVVIxyqEQvF2=	M4jtdFYwOjRiaB?=	NIf2[lJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR\|MuUUliY3;0doVifGWmIIfpeIghS1F?	MWCyOVk{PDJ\|Mh?=
U-87 MG	M3jn[WZ2dmO2aX;uJGF{e2G7	M2rEcVIxyqEQvF2=	MV:2M\|I1KGh?	NYLvWYhTcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT	MYmyOVk{PDJ\|Mh?=
HepG2	NVjGPXVHTnWwY4Tpc44hSXO\|YYm=	MmLqNlDDqM7:TR?=	MV62M\|I1KGh?	NGrWUpNl\WO{ZXHz[ZMhVEN\|LVnJJIRm\3KjZHH0bY9vyqCocn;tJFYhcA>?	M1zJbFI2QTN2MkOy
U-87 MG	NHHWXodHfW6ldHnvckBCe3OjeR?=	NXHxSo1UOjEEoN88US=>	NIHaTo83NzJ2IHi=	NFXUUHhqdmO{ZXHz[ZMhfGinIHH1eI9xcGGpaXOg[ox2gCBiYYSgOkBpKHeqaXzlJIlvcGmkaYTzJJRpcXNiZnz1fEBifCB{NHi=	MlnZNlU6OzR{M{K=
HepG2	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6yNE81OCEQvF2=	NFfFboEzPC92ODDo	NIHvdmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MkLqNlU6OzR{M{K=
U-87 MG	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK5fGpUOjBxNECg{txO	NWrQPXRPOjRxNEigbC=>	NGPa[GlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MXKyOVk{PDJ\|Mh?=
A549	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKwMlMuOTBizszN	MXOyOE84OiCq	NHTqbo9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	Mom1NlU3QTd6OUm=
H460	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[wMlMuOTBizszN	MVOyOE84OiCq	NV2wd5NUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MmHYNlU3QTd6OUm=
A549	NWnK[5YzSXCxcITvd4l{KEG\|c4PhfS=>	M33SNlEwOyEQvF2=	MUC0PEBp	M3TmTYlv\HWlZYOgZZBweHSxc3nz	Mo\jNlU3QTd6OUm=
H460	NYG0U4F3SXCxcITvd4l{KEG\|c4PhfS=>	M{i1NFEwOyEQvF2=	NHKwUnM1QCCq	MnLZbY5lfWOnczDhdI9xfG:\|aYO=	MYCyOVY6Pzh7OR?=
A549	MYfGeY5kfGmxbjDBd5NigQ>?	MXOzJO69VQ>?	NUnLZVdxQCCq	MoDnZoxw[2u\|IFHLWEBi[3SrdnH0bY9v	M2nyflI2Pjl5OEm5
H460	M2rGeGZ2dmO2aX;uJGF{e2G7	NEGybIk{KM7:TR?=	MkiwPEBp	MX7icI9kc3NiQVvUJIFkfGm4YYTpc44>	NYjrN3U{OjV4OUe4PVk>
A549	NIDaO3JHfW6ldHnvckBCe3OjeR?=	M{TPeFMh\|ryP	NXLlXWRiQCCq	MYjicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ?	MknnNlU3QTd6OUm=
H460	M{nWZWZ2dmO2aX;uJGF{e2G7	MYezJO69VQ>?	NVrjfmdmQCCq	MljUZoxw[2u\|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{	M1PhVFI2Pjl5OEm5
RMG1	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MnjwNU0{OCEQvF2=	Mmr2O\|IhcA>?	NF30[GZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MVuyOVUyQTF2OB?=
RMG2	MljuR4VtdCCYaXHibYxqfHliQYPzZZk>	M4PldlEuOzBizszN	MoC0O\|IhcA>?	MUXk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MUeyOVUyQTF2OB?=
KOC7C	NGrlbZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NU\Xc2d7OS1\|MDFOwG0>	NWfVO\|JLPzJiaB?=	MW\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MXeyOVUyQTF2OB?=
HAC2	M4PvcWNmdGxiVnnhZoltcXS7IFHzd4F6	NF;4ZpoyNTNyIN88US=>	M33scVczKGh?	NHzqcnZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NX\aWHdzOjV3MUmxOFg>
RMG2	NFXnbHNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MX2xMVMxKM7:TR?=	Mmr4OFghcA>?	NYjreYdq\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M{fOZlI2PTF7MUS4
OVISE	M3TVOGNmdGxiVnnhZoltcXS7IFHzd4F6	NUO3PW1GOS1\|MDFOwG0>	M1rEe\|Q5KGh?	Mkez[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NVHYfoZFOjV3MUmxOFg>
SKOV3	NVLsc\|lpS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlexNU0{OCEQvF2=	MYi0PEBp	MmDK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MWmyOVUyQTF2OB?=
A2780	MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1\sNVEuOzBizszN	M37jPFQ5KGh?	MljR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MoToNlU2OTlzNEi=
RMG1	NIj2d3ZCeG:ydH;zbZMhSXO\|c3H5	Ml\ZN\|Ah\|ryP	MWmyOEBp	NWPmcWw{cW6mdXPld{BieG:ydH;zbZM>	M3m4OFI2PTF7MUS4
RMG2	NEPG[5NCeG:ydH;zbZMhSXO\|c3H5	NHvaS3M{OCEQvF2=	MV:yOEBp	NVXUZop7cW6mdXPld{BieG:ydH;zbZM>	MXSyOVUyQTF2OB?=
HCC1806	NVv5TFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYmwMVExKM7:TR?=	MUm0PEBp	MkfzSWM2OD1{Lki05qCKyrIkgJmwMlA4KM7:TR?=	MmnxNlUzQTN3N{[=
MDA-MB-231	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljjNE0yOCEQvF2=	M1[5UlQ5KGh?	MoW3SWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?=	M4XFXVI2Ojl\|NUe2
GL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[wMlHjiJNzMEFihKnPxE1?	NWHBWndWPDhiaB?=	M1fGd2lEPTB;OT65NUDPxE1?	MYOyOFg5OTVyOB?=
CLBL-1	NU\PN2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSwMlHjiJNzMEFihKnPxE1?	Mkm5OFghcA>?	MV7JR\|UxRTN\|LkCg{txO	MnfONlQ5QDF3MEi=
UL-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL6WFIxNjIkgKOxNFDjiIoQvF2=	NFSwRY41QCCq	MmXoTWM2OD15LkCxJO69VQ>?	MWSyOFg5OTVyOB?=
Ema	NYjFNZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm2NE4y6oDVMUCw5qCK\|ryP	MV:0PEBp	MWLJR\|UxRTV6Lkeg{txO	MVWyOFg5OTVyOB?=
PANC-1	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHlNE0zPSEQvF2=	MlO2O\|IhcA>?	M1G5NIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	Moq0NlQ2OTl5NUG=
MIA	NV;hfY11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHkbHYxNTJ3IN88US=>	NV7kOGl[PzJiaB?=	MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M{e0cVI1PTF7N{Wx
AsPC-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIK2eWwxNTJ3IN88US=>	M{TIVFczKGh?	M1fZ[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NGXvVpEzPDVzOUe1NS=>
PANC-1	NUK4NJpXTnWwY4Tpc44hSXO\|YYm=	MnXsNE42KM7:TR?=	NWXrNY9IOjRiaB?=	M2nGeolvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	MnPLNlQ2OTl5NUG=
MIA	Mnn4SpVv[3Srb36gRZN{[Xl?	MlXQNE42KM7:TR?=	M1XKSVI1KGh?	MW\pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;uxsA>	NWnFTINQOjR3MUm3OVE>
AsPC-1	M{D3XWZ2dmO2aX;uJGF{e2G7	MlSwNE42KM7:TR?=	MVuyOEBp	MoTtbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh	NGLCPXIzPDVzOUe1NS=>
U87MG	NEDK[W5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEmzU2wxNTJ3IN88US=>	MojENlQuQTZiaB?=	MmLy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MlnMNlQxPjV3MkK=
SGC7901	NF\FPJlHfW6ldHnvckBCe3OjeR?=	M2XWSVAvPzVxMUFCpO69VQ>?	MnriOFghcA>?	MWHk[YNz\WG\|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy\|wrC=	NEjOeGszOzlzMkK0Oi=>
MGC803	M1HYSmZ2dmO2aX;uJGF{e2G7	NUPyR3d7OC55NT:xNOKh\|ryP	M1LieFQ5yqCq	NWDkSmRM\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh	NFfXbG0zOzlzMkK0Oi=>
TykNu	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH3qbZpKSzVyPUOuOUDPxE1?	M2P1NlI{QDd5MEGy
TykNuR	NYG1R2NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXTwfWI6UUN3ME21MlUh\|ryP	NX3Henc4OjN6N{ewNVI>
M41	NVjNVJM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYHJR\|UxRTJ2Lkeg{txO	MXKyN\|g4PzBzMh?=
M41R	NX3KUIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2PXeWlEPTB;MUmuPEDPxE1?	MkLrNlM5PzdyMUK=
OVCAR8	NGPqOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXnJR\|UxRTNzLkGg{txO	NYPpW2lKOjN6N{ewNVI>
HeyA8	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1m4b2lEPTB;MkSuN{DPxE1?	NVv6WWlUOjN6N{ewNVI>
A2780CP	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4fLXmlEPTB;Nz62JO69VQ>?	MV6yN\|g4PzBzMh?=
OVCAR5	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1nyeGlEPTB;Nj63JO69VQ>?	NX;xTmZXOjN6N{ewNVI>
A2780S	NVLRZolCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1nzbmlEPTB;MUSuOUDPxE1?	M1P3eVI{QDd5MEGy
MCAS	NGW5eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYHPS5JKUUN3ME2xNk42KM7:TR?=	MofYNlM5PzdyMUK=
NCI-H727	NHX3WJdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3LqR\|AuOTByIN88US=>	MViyOE84OiCq	NHHWTWRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MkLKNlI1QTl2M{e=
GOT1	MoPQR4VtdCCYaXHibYxqfHliQYPzZZk>	MViwMVExOCEQvF2=	NEfjepQzPC95MjDo	NWrJTndy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NGO5NGczOjR7OUSzOy=>
BON1	NEnBTVJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3:2WlAuOTByIN88US=>	MmnENlQwPzJiaB?=	NHHON\|hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	Mn64NlI1QTl2M{e=
BON1	M1qyfGFxd3C2b4Ppd{BCe3O\|YYm=	M{HUTVAuOTBizszN	NUfJbVh5OjRiaB?=	MnLhbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	Ml3DNlI1QTl2M{e=
BON1	NEK1eWhHfW6ldHnvckBCe3OjeR?=	M{L3PFcvPS9zMDFOwG0>	M{\OSVghcA>?	MXLk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[geIhmKGGwdHmtZZBweHSxdHnjJJBzd3SnaX7zJGJEVDJiYX7kJGJkdC2[TB?=	MkGxNlI1QTl2M{e=
Kasumi-1	NF\xdplE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHnTVHMxNTJyIN88US=>	M{G0[lI1NzR6IHi=	Mmfs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NWLOVGZSOjJ2MEeyNlg>
HL-60	NIjtZWpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3jEXFAuOjBizszN	MVSyOE81QCCq	MX\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MVKyNlQxPzJ{OB?=
Kasumi-1	M4jo[WFxd3C2b4Ppd{BCe3O\|YYm=	NEPrZWQyOCEQvF2=	NU[1[\|RnOjRiaB?=	M3nzXIlv\HWlZYOgZZBweHSxc3nz	M1f1OlIzPDB5MkK4
HL-60	M3\pO2Fxd3C2b4Ppd{BCe3O\|YYm=	NVTIVGVROTBizszN	MnjuNlQhcA>?	M{Kwc4lv\HWlZYOgZZBweHSxc3nz	MX6yNlQxPzJ{OB?=
Kasumi-1	MkC1SpVv[3Srb36gRZN{[Xl?	MXGyMlUwPS9zMDFOwG0>	NYjsO2NuOjRiaB?=	NUfGT496\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy\|wrDkc5NmNWSncHXu[IVvfGy7	MoTyNlI1ODd{Mki=
HL-60	NYfNdGhmTnWwY4Tpc44hSXO\|YYm=	MVeyMlUwPS9zMDFOwG0>	MmnINlQhcA>?	M2W2UoRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>?	M1niW\|IzPDB5MkK4
Kasumi-1	M4XSdWZ2dmO2aX;uJGF{e2G7	Ml\xNk42NzVxMUCg{txO	M3zSWFI1KGh?	MVvpcoR2[2W\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NXzxWG06OjJ2MEeyNlg>
HL-60	NYDXV29QTnWwY4Tpc44hSXO\|YYm=	MXeyMlUwPS9zMDFOwG0>	MWKyOEBp	M2rhRolv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM\|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NFPBNVczOjRyN{KyPC=>
K562	NYnNRo5[TnWwY4Tpc44hSXO\|YYm=	NFPPOWYzOCEQvF2=	M3HkU\|Q5KGh?	M2q1S4lv\HWlZYOgZZV1d3CqYXf5xsA>	MmGzNlI1ODd{Mki=
OCUT1	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuwMlEuOyEQvF2=	MnexOUBl	MmDJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M4r4[lIzODlyMkex
K1	M{XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKwMlEuOyEQvF2=	M2HqV\|Uh\A>?	MoPxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MlK4NlIxQTB{N{G=
OCUT1	NF;TfWRHfW6ldHnvckBCe3OjeR?=	NX7POoFCOyEQvH2=	MljNNlQhcA>?	MkfwZ4F2e2W\|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>?	M2K2dVIzODlyMkex
CaOV3	NXfaOINrS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUSxM\|UwOTBizszN	NUKxbGEyPDhiaB?=	M4rjNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6ncjDjc5Rz\WG2ZXSge4l1cCCyYXPsbZRigGWu	MoTZNlE4PzVyNUS=
SKOV3	MlyyR5l1d3SxeHnjbZR6KEG\|c3H5	NFK1W202KM7:TR?=	MXi0PEBp	NYnEb4R1\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>?	M13JUVIyPzd3MEW0
A2780	M4ixc2N6fG:2b4jpZ4l1gSCDc4PhfS=>	NFfrWGI2KM7:TR?=	MWK0PEBp	NWDBTolz\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>?	M2jLWVIyPzd3MEW0
HT-29	MkDmR5l1d3SxeHnjbZR6KEG\|c3H5	NXzQZplCPSEQvF2=	NFTCNnc1QCCq	MXHlcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg	MYmyNVc4PTB3NB?=
A498	NGTicodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13PWlAuPDBizszN	MVK3NkBp	NWHP[FVbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NWLsUWI1OjF4NESwOVA>
CAKI-1	NWH1T2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn64NE01OCEQvF2=	NVj0V45CPzJiaB?=	MkL4TWM2OH5zMDFOwG0>	NV3DZ3lUOjF4NESwOVA>
769-P	M1nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIe5elUxNTRyIN88US=>	M3XBNlczKGh?	NYXxSXhPUUN3MI61MVExKM7:TR?=	MVGyNVY1PDB3MB?=
786-0	MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWiwMVQxKM7:TR?=	NYrjenFWPzJiaB?=	MmXsTWM2OH53IN88US=>	NGHHTYwzOTZ2NEC1NC=>
786-O	NVLyeZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3pNE0zOCEQvF2=	Mn;jO\|IhcA>?	MmCybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MknoNlE3PDRyNUC=
CAKI-1	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXGNE0zOCEQvF2=	NYewOJhMPzJiaB?=	MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NIG1SoozOTZ2NEC1NC=>
769-P	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\Xe4IxNTJyIN88US=>	Mk\lO\|IhcA>?	MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NXnRS4xNOjF4NESwOVA>
A498	NGrkc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn6NE0zOCEQvF2=	NHLIUlY4OiCq	Mk\BbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NGP4UXgzOTZ2NEC1NC=>
CWR22RV1	NHvSe\|FE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXLTW4pUOTBizszN	Mmi5NlQhcA>?	MVrpcoNz\WG\|ZYOgd4Vve2m2aY\peJkhd2ZiaIXtZY4hS1eUMkLSWlEh[2WubIOgeI8hemGmaXH0bY9v	MWmyNVQ6PjJ5Mx?=
CWR22RV1	NXSyXlJHSXCxcITvd4l{KEG\|c4PhfS=>	NIfuOZcyOCEQvF2=	MkPKNlQhcA>?	NEL3VJRmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM>	M2rV[lIyPDl4Mkez
CWR22RV1	MnXvSpVv[3Srb36gRZN{[Xl?	NYP5bVRuPSEQvF2=	MWmyOEBp	MlPKdoVlfWOnZDDwbI9{eGixconsZZRqd25ib3[gRYt1KHOrZ37p[olk[W62bIm=	NWjpenBxOjF2OU[yO\|M>
HepG2	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nEZVUwOTBxMkCvOFAh\|ryP	MnrRNlQwPDhxN{KgbC=>	MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M{fRbFIxQDR{NEK1
Bel-7402	NIfXZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPuSI42NzFyL{KwM\|QxKM7:TR?=	Ml\pNlQwPDhxN{KgbC=>	Mnq0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NGf0VI4zODh2MkSyOS=>
HepG2	M3H3[GZ2dmO2aX;uJGF{e2G7	MVG1M\|ExNzJyIN88US=>	M2rpRlI1KGh?	M1uzOpJme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG\|ZR?=	NX\4eHptOjB6NEK0NlU>
Bel-7402	M3jJV2Z2dmO2aX;uJGF{e2G7	Mkj0OU8yOC9{MDFOwG0>	NGG0[VkzPCCq	NU\LWoVRemW\|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl	NFfYVXIzODh2MkSyOS=>
HepG2	M1q2cmFxd3C2b4Ppd{BCe3O\|YYm=	NGLRVmY2NzFyL{KwJO69VQ>?	MmXsNlQwPDhiaB?=	NVK4VY1ScW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=>	MoDuNlA5PDJ2MkW=
Bel-7402	MXjBdI9xfG:\|aYOgRZN{e2G7	NUjBZ3ZCPS9zMD:yNEDPxE1?	M3fjWVI1NzR6IHi=	M4HxT4lv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW=	MVqyNFg1OjR{NR?=
OAW-42	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH3NHdXOC12MDFOwG0>	NGXXeYc4OsLiaB?=	M{XmbGlEPTC-MUCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MnPxNlA1ODV{OU[=
PA-1	M4DhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2S4XFAuPDBizszN	MoHHO\|LDqGh?	MVXJR\|UxhjJ3IN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NV7jc\|N[OjB2MEWyPVY>
SKOV3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHR[WtsOC12MDFOwG0>	NXX0WFI{PzMEoHi=	MkPmTWM2OH5\|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NGnjfmMzODRyNUK5Oi=>
A2780	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\tUoUxNTJyIN88US=>	NGWwOWw1QC95MjDo	M1rLWGlEPTEEoE5CpFPDqM7:bR?=	M2jJblIxPDB3Mkm2
A2780cis	NF7BfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjDXJJkOC1{MDFOwG0>	MW[0PE84OiCq	NHW4UmhKSzVywrC9xsA3yqEQvH2=	NXfWUmJqOjB2MEWyPVY>
SKW6.4	NEjEd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW1Sm9mOi1zMNMg{txO	NF\ndI81QMLiaB?=	M1\rVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NWTES3IyOjBzM{C5OlA>
MAVER	M2DGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfmdY5pOi1zMNMg{txO	NXH6SJg4PDkEoHi=	MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MUeyNFE{ODl4MB?=
BJAB	NXP3S45qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvMcpUzNTFywrFOwG0>	MYO0POKhcA>?	NH;yVXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M1HUXVIxOTNyOU[w
OCI	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVyyMVExyqEQvF2=	MX20POKhcA>?	NHi2WnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M4HoelIxOTNyOU[w
MOLM	M3;aV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPrb\|gzNTFywrFOwG0>	NV\peId[PDkEoHi=	NYfHZY5LcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MXKyNFE{ODl4MB?=
HL-60	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWyMVExyqEQvF2=	MWe0POKhcA>?	NGfxPVBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MoDYNlAyOzB7NkC=
SKW6.4	NIm1fIpCeG:ydH;zbZMhSXO\|c3H5	MnHtNVDDqM7:TR?=	M1PjU\|I1NzR6IHi=	NUC4b\|lmcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>	NXzabm4yOjBzM{C5OlA>
MAVER	M4Xj[GFxd3C2b4Ppd{BCe3O\|YYm=	MX6xNOKh\|ryP	NEnLUXgzPC92ODDo	NELvWYhqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	NGroc4EzODF\|MEm2NC=>
BJAB	M{\HPGFxd3C2b4Ppd{BCe3O\|YYm=	NWr1SJhoOTEEoN88US=>	NUjHdHptOjRxNEigbC=>	MWnpcoR2[2W\|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7	MmK1NlAyOzB7NkC=
OCI	NGTneZZCeG:ydH;zbZMhSXO\|c3H5	M1K1UFExyqEQvF2=	M2CyZlI1NzR6IHi=	NYDhZWJucW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>	Ml3DNlAyOzB7NkC=
MOLM	M4\vcGFxd3C2b4Ppd{BCe3O\|YYm=	MkPINVDDqM7:TR?=	MXKyOE81QCCq	MoPubY5lfWOnczDhdI9xfG:\|aYOgeIlu\S2mZYDlcoRmdnSueR?=	MYWyNFE{ODl4MB?=
HL-60	MmnFRZBweHSxc3nzJGF{e3OjeR?=	MYexNOKh\|ryP	MU[yOE81QCCq	NUD2UIFjcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>	MVmyNFE{ODl4MB?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-S6K1 / S6K1 ; PubMed: 25519148 Mol Cancer Res The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies. PARP; PubMed: 25519148 Mol Cancer Res Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; PubMed: 19920197 Cancer Res The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h. p-PDK1 / p-GSK3α/β / p-S6R ; PubMed: 17761832 Blood BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies.	25519148 19920197 17761832
Growth inhibition assay	Cell viability; PubMed: 28332584 Sci Rep Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.	28332584

In vivo

Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]

Protocol

Kinase Assay:^[3]	- Collapse Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:^[2]	- Collapse Cell lines: Human glioma cell lines Concentrations: 0, 15, 30 and 45 μM Incubation Time: 48 hours Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old). Formulation: 0.9% NaCl solution Dosages: 250 mg/kg/wk or 36 mg/kg/d Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Ethanol	15 mg/mL (32.49 mM)
	Water	8 mg/mL (17.32 mM)
	DMSO	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Perifosine (KRX-0401) SDF

Molecular Weight	461.66
Formula	C₂₅H₅₂NO₄P
CAS No.	157716-52-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC639966

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01224730	Completed	Drug: perifosine	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Drug: perifosine + temsirolimus	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Drug: Perifosine\|Drug: Capecitabine	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Drug: perifosine	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : AKT2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.
Akt Inhibitor in Clinical Trial

Ipatasertib (GDC-0068) : Phase II for Prostate Cancer and Gastric Cancer.
Newest Akt Inhibitor

AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.
A-674563

A-674563 is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.
Triciribine

Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol

Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)

Cited by 88 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Perifosine (KRX-0401) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)

Cited by 88 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Perifosine (KRX-0401) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)